CD44-Targeted Liposomal Nanocarriers for Vulnerable Plaque Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vulnerable plaques, such as oral administration of statins, suffer from low bioavailability and significant side effects due to systemic drug delivery, and there is a lack of targeted drug delivery systems that can effectively stabilize vulnerable plaques with high specificity and stability.
Innovation Solution
A liposome nanocarrier delivery system is developed that targets activated CD44 molecules on vulnerable plaques using hyaluronic acid or its derivatives as ligands, allowing for stable and sustained drug release, enhanced by loading with CD44 activators to amplify targeting affinity and overcome endogenous HA barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic administration of drugs (e.g., oral statins) is used to treat vulnerable plaques, then the drugs can reach the lesion site through blood circulation, but the bioavailability is low and toxic side effects occur due to widespread distribution
Solution Approach 1:
The patent uses CD44 molecules as intermediaries to mediate drug delivery to vulnerable plaques. The liposome nanocarrier is designed to specifically bind to activated CD44 molecules on the plaque surface, enabling targeted delivery. This intermediary mechanism allows the drug to concentrate at the lesion site while minimizing systemic distribution and associated side effects.
Solution Approach 2:
The invention creates local quality by modifying the liposome surface with specific ligands (such as hyaluronic acid or anti-CD44 antibodies) that recognize and bind to activated CD44 molecules only at vulnerable plaques. This localized recognition ensures that the therapeutic effect is concentrated at the target site while normal tissues receive minimal drug exposure.
2Reliability
If targeted drug delivery systems are developed to increase drug concentration at the target site, then therapeutic efficacy is improved, but the device complexity increases due to the need for specific targeting mechanisms
Solution Approach 1:
The patent employs composite liposome nanocarriers that integrate multiple functional components: a lipid bilayer structure for drug encapsulation, surface-modified ligands for CD44 targeting, and potentially activators for enhanced binding. This composite structure achieves reliable targeted delivery while maintaining a relatively simple overall design compared to more complex engineered systems.
Solution Approach 2:
The invention utilizes parameter changes in the CD44 molecule itself - specifically, the activation state of CD44 on vulnerable plaques versus normal cells. By targeting the activated form of CD44 that is upregulated on plaques, the system achieves high specificity without requiring complex engineering, leveraging natural biological parameter differences.
3Duration of action of moving object
If liposome nanocarriers are used for targeted delivery, then sustained drug release is achieved, but the manufacturing precision requirements increase due to the need for controlled drug encapsulation and surface modification
Solution Approach 1:
The patent applies preliminary action by pre-modifying the liposome surface with targeting ligands and pre-encapsulating the drug during the liposome formation process. This simultaneous encapsulation and surface modification approach, performed before administration, ensures controlled drug release kinetics and stable targeting functionality without requiring post-manufacturing adjustments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves specific targeting and sustained drug release at vulnerable plaques, increasing therapeutic efficacy while reducing systemic side effects by maintaining high drug concentrations locally.
Implementation Method 1
the targeting ligand is a ligand capable of specifically binding to the activated CD44 molecule
Implementation Method 2
The nanocarrier is loaded with a substance for preventing and/or treating the vulnerable plaque or a disease associated with the vulnerable plaque, and the nanocarrier releases the loaded substance in a stable and sustained manner
Data Source
AI summary
A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.